Tempus AI's stock plummeted 5.18% during intraday trading on Wednesday, extending losses from earlier in the session.
The precision medicine technology company reported fourth-quarter results that exceeded analyst expectations. However, the stock came under pressure as the company's 2026 revenue guidance failed to significantly surpass Wall Street estimates, disappointing investors.
Adding to the negative sentiment, multiple analyst firms, including Needham, Stifel, TD Cowen, BTIG, and JPMorgan, cut their price targets on the stock following the earnings report, contributing to the downward movement.